What did the rodent studies show?

GLP-1 receptor agonists activated thyroid C-cells in rats and mice, causing calcitonin release and proliferation, progressing to hyperplasia and in some animals tumours.

What does 'on-target' mean?

That the effect proceeds through the intended receptor rather than an unrelated interaction — a predictable consequence of the pharmacology in that species.

GLP-1 & Incretin Science

Where the Thyroid Warning Came From

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Bjerre Knudsen and colleagues reported in Endocrinology in 2010 that GLP-1 receptor agonists activate rodent thyroid C-cells, causing calcitonin release and C-cell proliferation. That finding, replicated and characterised as on-target, is the origin of the boxed warning.

Key facts

Foundational paper: Bjerre Knudsen 2010, Endocrinology
PMID: 20203154
Species: Rats and mice
Observed: Calcitonin release, C-cell proliferation
Characterisation: On-target, receptor-mediated
Follow-up: Rosol 2013, Toxicol Pathol (PMID 23471186)

What C-cells are

Parafollicular cells in the thyroid that produce calcitonin, a hormone involved in calcium handling. They are a minority population and distinct from the follicular cells that make thyroid hormone — which is why medullary thyroid carcinoma, arising from C-cells, is a different disease from the far commoner papillary and follicular thyroid cancers.

What was observed

In rats and mice given GLP-1 receptor agonists, C-cells released calcitonin and proliferated. With sustained exposure this progressed to C-cell hyperplasia and, in some animals, to tumours. The 2010 Endocrinology paper established the sequence rather than merely reporting an endpoint, which is what made it persuasive.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why on-target is the important descriptor

Rosol and colleagues characterised these as on-target effects in Toxicologic Pathology in 2013. On-target means the effect proceeds through the intended receptor rather than through an unrelated interaction or a contaminant. That makes it a predictable consequence of the pharmacology in that species — and it also means the effect should be expected wherever the receptor is present at sufficient density, which becomes the crux of the human question.

Why regulators acted on a rodent finding

Because a receptor-mediated proliferative effect in two species is a serious signal, and medullary thyroid carcinoma is a condition where caution is cheap relative to the consequence. The resulting boxed warning contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

The question the rodent work raises but cannot answer

Whether human C-cells behave the same way. An on-target effect depends on the target being present, and receptor expression differs between species more often than is assumed. That question was addressed directly by later work, and the answer is not what a straightforward reading of the rodent data would predict.

What this concerns

Licensed medicines assessed by regulators, and toxicology conducted under regulated conditions. Nothing supplied on this site is a GLP-1 receptor agonist, and none of this literature describes anything sold here.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What did the rodent studies show?: GLP-1 receptor agonists activated thyroid C-cells in rats and mice, causing calcitonin release and proliferation, progressing to hyperplasia and in some animals tumours.
What does 'on-target' mean?: That the effect proceeds through the intended receptor rather than an unrelated interaction — a predictable consequence of the pharmacology in that species.
What does the boxed warning say?: It contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum